GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
Erola Pairo‐Castineira(Roslin Institute), Adam Brown(Roslin Institute), Latha Aravindan(Roslin Institute), Seán Keating(Edinburgh Royal Infirmary), Lucija Klarić(Institute of Genetics and Cancer), Isar Nassiri(Centre for Human Genetics), Manu Shankar‐Hari(Centre for Inflammation Research), Jonathan Millar(Roslin Institute), Peter Openshaw(Imperial College London), Tomas Malinauskas(University of Oxford), Anne Richmond(Edinburgh Cancer Research), Augusto Rojas-Martı́nez(Universidad Autónoma de Nuevo León), Wilna Oosthuyzen(Roslin Institute), Lowell Ling, Ting Qi(The University of Queensland), Johnny Millar(Royal Children's Hospital), Timothy Walsh(Duke University), Pablo Lapunzina(Hospital Universitario La Paz), Glenn A. McConkey(University of Leeds), Albert Tenesa(Roslin Institute), Charlotte Summers(Queen Mary University of London), Daniel F. McAuley(Queen's University Belfast), Konrad Rawlik(Roslin Institute), Alistair Nichol(University College Dublin), Athanasios Kousathanas(Jackson Laboratory), Hugh Montgomery(University College London), Julian C. Knight(Chinese Academy of Medical Sciences & Peking Union Medical College), Peter Horby, Malcolm G. Semple(University of Liverpool), Fiona Griffiths(Roslin Institute), Carlos Flores(Universidad de La Laguna), Ryan S. Thwaites(University of Oxford), Sara Clohisey(Roslin Institute), David M. Maslove(Queen's University), Andrew D. Bretherick(NHS Tayside), Colin B. Begg(Memorial Sloan Kettering Cancer Center), Marie Zechner(Roslin Institute), Yang Wu(Liverpool School of Tropical Medicine), Clark D Russell(Centre for Inflammation Research), Kirstie Morrice(Western General Hospital), Emma Aitkin(Roslin Institute), José A. Riancho(Universidad de Cantabria), Ruth Armstrong(Addenbrooke's Hospital), Heather Biggs(University of Cambridge), Ceilia Boz(Roslin Institute), Charles Hinds(William Harvey Research Institute)
Cited by 223
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k